Despite decades of discourse, there is still no global agreement on what constitutes a safe dose or even where the boundary lies between a supplement and a medicine. The controversy stems from the paradox that monacolin K, produced naturally through the fermentation of traditional red yeast rice, is chemically identical to the cholesterol-lowering drug Lovastatin.
That dual identity has driven sharply different regulatory outcomes across countries: It is treated as a food in China, a functional supplement in Japan, a regulated medicine in Australia, an unapproved drug in the United States and an up-until-recently permitted supplement in Europe.
The biochemical overlap has set off a chain reaction that has pulled food traditions, nutritional science and pharmaceutical regulation into the same debate. To understand this how one molecule ended up splitting global policy, we must go back to where it first began.
1970s: Discovery of Monacolin K and the origins of statin drugs
Monacolins are a group of naturally occurring compounds produced by certain fungi in fermented foods, most notably in red yeast rice, which is rice fermented with the mold Monascus purpureus.
Red yeast rice has been used in China for over a thousand years as both a food colorant and medicinal ingredient. It appears across a long lineage of Chinese medical and dietary literature, described as helping with digestion and blood circulation.
In the 1970s, Japanese microbiologist Akira Endo identified cholesterol-lowering compounds produced by fungi, including monacolin K–related substances. His research established that these compounds inhibit the enzyme HMG-CoA reductase, a key regulatory step in cholesterol biosynthesis.
Around the same time, scientists at the U.S. pharmaceutical company Merck isolated a structurally related compound from Aspergillus terreus, a species of filamentous fungus, and developed it into Lovastatin, one of the first approved statin medications.
Appetite for red yeast rice supplements began to grow in Western markets in the 1980s, yet after the Food and Drug Administration (FDA) approved Lovastatin in 1987, regulators began treating high-dose red yeast rice products more cautiously because they contained the same active compound.
Beginning in the 1990s, red yeast rice supplements were marketed alongside pharmaceuticals as a “natural” remedy for lowering cholesterol.
This created regulatory and safety debates, as some red yeast rice products contain pharmacologically active levels of monacolin K, while others contain very little, making their effectiveness inconsistent.
1997: US court rules red yeast rice acts like a prescription drug
When the U.S. Congress passed the Dietary Supplement Health and Education Act (DSHEA) in 1994, companies began officially marketing red yeast rice as a dietary supplement.
Not long after, however, the FDA began to reassess whether these products should be regulated as supplements at all. The agency’s position became that if a product contained a compound that is already an approved drug, and it is being marketed for therapeutic effect like lowering cholesterol, then it fell under drug regulation.
In one of the earliest and most important tests of DSHEA’s “drug preclusion” clause, the FDA challenged dietary supplement company Pharmanex in 1997 after it found that its Cholestin product contained significant levels of monacolin K. The agency argued that this made Cholestin an unapproved drug and ordered Pharmanex to stop marketing it as a dietary supplement, asserting that it had to undergo the full drug-approval process — including safety and efficacy testing — before it could be sold.
This action triggered a legal dispute. Pharmanex contested that red yeast rice was a traditional food-derived product protected under DSHEA and should remain in the supplement category, while the FDA sought to enforce its designation as an unapproved drug.
In 1998, the courts backed the FDA, confirming red yeast rice products with drug-level monacolin K can be regulated as drugs. That position was upheld on appeal in 2001.
2011: EFSA opens the door for red yeast rice cholesterol claims
Reports began to emerge that commercially available red yeast rice supplements varied widely in their active ingredient content. In product testing, researchers detected large differences in monacolin K levels and also identified the contaminant citrinin in about one-third of products tested.
Despite this and in contrast to North America’s pharma stance, in 2011, the European Food Safety Authority (EFSA) engaged in an assessment of monacolin K as a supplement, issuing a key scientific opinion that there was a clear cause-and-effect relationship between consuming monacolin K from red yeast rice and maintaining normal LDL cholesterol levels.
EFSA specifically found that a daily intake of 10 mg of monacolin K was effective, leading the European Commission to authorize a health claim for monacolin K from red yeast rice in 2012. This marked a turning point for supplement manufacturers across Europe, which could now market red yeast rice products with an officially approved cholesterol-related claim.
The approved wording eventually became: “Monacolin K from red yeast rice contributes to the maintenance of normal blood cholesterol concentrations.”
Validating the efficacy of the compound remained the primary focus for EFSA at the time, drawing a significant share of its scientific attention and delaying a stronger regulatory emphasis on safety. As a result, although a more precautionary approach had already begun to emerge in North America, safety concerns in Europe did not gain significant regulatory traction until several years later.
2013: Health Canada sets prescription threshold for monacolins
Health Canada, the country’s federal health regulator, established its current approach to monacolins in the early 2010s following a regulatory review and consultation process that concluded in 2013.
It clarified that products delivering pharmacologically meaningful amounts of monacolin K should not be regulated as natural health products that effectively function as statin drugs.
As a result, Health Canada aligned these substances with the Prescription Drug List, setting a practical threshold of about 1 mg or more of monacolins per day, above which products are generally treated as prescription medicines due to safety, dosing consistency and adverse-effect concerns.
2013: EFSA defends Monacolin K requirement as lower-dose evidence emerges
The monacolin K market in Europe remained uninterrupted until an EFSA announcement in 2013 reaffirmed support for monacolin K from red yeast rice at a daily intake of 10 mg.
This was prompted by a new application involving a proprietary red yeast rice ingredient developed by Sylvan Bio, which EFSA concluded worked the same way as monacolin K in other red yeast rice products—again finding a clear cause-and-effect relationship between consuming monacolin K and maintaining normal blood cholesterol levels.
Around this time, industry discussions began to surface suggesting that lower doses should also qualify for the health claim.
Several studies were starting to indicate that even lower doses of monacolin K could produce meaningful LDL-cholesterol–lowering effects. However, EFSA maintained that consumers needed to take 10 mg per day to achieve the claimed cholesterol benefit.
2018: EU safety review raises concerns over monacolin K
Over the next five years, red yeast rice products became more widely available online and in health shops and were increasingly used by people already taking statins or managing cholesterol issues. This prompted closer scrutiny from regulators, who began to express concern that exposure to monacolin K was not just a question of whether the products worked, but whether they were safe at all under real-world use.
In June 2018, EFSA shifted its focus from efficacy to safety and issued a much more cautious assessment of monacolin K in red yeast rice supplements, publishing an opinion concluding that monacolins from red yeast rice could not be considered safe for consumers.
After reviewing reported adverse events and clinical safety data, EFSA concluded that daily intake levels at or above 10 mg of monacolin K could lead to serious health risks.
The panel noted that even as little as 3 mg per day might not be considered safe for consumers, particularly when taken without medical supervision or alongside other statin medications.
2019: EU sets citrinin limit in red yeast rice supplements
In 2019, the European Commission introduced a regulatory limit on citrinin, the toxic mycotoxin that can occur in fermented products like red yeast rice.
Citrinin targets the kidneys where it can disrupt normal cellular function, trigger oxidative stress and damage renal tubule cells responsible for filtering waste from the blood. With prolonged exposure, these effects can impair kidney function and contribute to structural kidney injury.
The regulation set a maximum permitted level of 100 µg/kg in red yeast rice products, marking a significant step toward tighter safety controls for this category of supplements across the EU.
2022: Lower dosage and stronger warnings
In response to the growing concerns about the risks associated with monacolin exposure, the EU announced a maximum daily intake of 3 mg of monacolins in 2022, along with requirements for prominent warning labels on all products containing them.
Labels were required to clearly state that the products are not suitable for certain groups, including pregnant or breastfeeding women, children, people over 70 and individuals already taking cholesterol-lowering medication such as statins.
By this point, the UK had left the European Union, meaning regulation in Great Britain was governed by the Food Standards Agency (FSA) rather than updated EU rules. The FSA followed a precautionary approach consistent with broader safety concerns around red yeast rice supplements, but even now has still not announced its official position.
2024: Monacolin K health claims effectively banned
In mid 2024, the EU restricted monacolins from red yeast rice after EFSA concluded they posed safety risks even at low intakes.
Acting on this advice, the European Commission adopted rules that effectively removed these substances from standard food supplement use and required strict warnings where traces remain.
As a result, companies could no longer market these products as cholesterol-lowering supplements, since the ingredient is no longer considered safe under permitted conditions of use.
2024: Major safety incident triggers scrutiny in Japan
In 2024, a major food-safety crisis erupted in Japan when Kobayashi Pharmaceutical recalled its red yeast rice supplements (beni-koji) after health authorities and investigators linked them to severe kidney damage. Authorities reported more than 100 fatalities and hundreds of hospital admissions recorded among exposed users.
The company halted production and announced a full recall after over 50 cases of hospitalization and two suspected deaths following 18.5 tonnes of production and distribution to supplement manufacturers the previous year.
Regulators in both Japan and Taiwan moved quickly to contain the issue. Taiwan’s Food and Drug Administration suspended sales and imports of affected products, ordered recalls from local manufacturers using the ingredient and issued warnings of penalties for non-compliance. As the investigation expanded, regulators and medical reports linked certain contaminated batches to acute renal injury and later testing identified fungal metabolite puberulic acid as a suspected toxic compound.
Japan’s response triggered a wider ripple effect across East Asia, prompting South Korean authorities to issue consumer advisories and safety warnings about imported or similar dietary supplements and to strengthen monitoring of nutraceutical imports.
In the aftermath, Japan tightened its regulatory framework, announcing that from Sept. 1, 2026, it will extend Good Manufacturing Practice (GMP) requirements to Foods with Function Claims (FFC), alongside new labeling rules, following a two-year grace period.
2025: EFSA deems monacolins unsafe at any dose
In 2025 EFSA delivered a major blow to industry, following up its scientific opinion with the release of a final opinion that deemed monacolins unsafe at any dose. It warned that even low daily doses may trigger serious health problems such as liver damage and rhabdomyolysis.
Despite previous revisions to a safe dose at 3 mg per day and submissions from industry stakeholders during the EU’s scrutiny period, a panel concluded that there is no established safe dose for monacolin K and highlighted variability in supplement composition and potential contaminants as major additional safety concerns.
2026: European Commission notifies World Trade Organization of planned ban on monacolins
On March 4, 2026, the European Commission notified the World Trade Organization of a proposal to prohibit the use of monacolins from red yeast rice in food supplements.
It is forecast that the ban will take effect the third quarter of this year, followed by a 12-month grace period during which companies must clear existing stock. After this transition period, the EU is expected to fully enforce the ban, prohibiting all products containing monacolins.
Commenting on the looming ban, Jerome Le Bloch, head of scientific affairs at Foodchain ID, noted that it applies only to monacolins from red yeast rice and not to red yeast rice itself, meaning that red yeast rice products without monacolins could still be authorized.
Looking to the future of cholesterol supplements
The 50-year-long debate continues to divide, with some experts saying suppliers have been backed into a corner.
Miguel Florido, a nutraceutical formulation consultant with a focus on cardiometabolic health, said that removing monacolins will create a significant therapeutic gap, as they have been among the most effective lipid-lowering nutraceuticals due to their statin-like activity.
“In the short term, I believe the category will rely much more on rational multi-ingredient formulations than on the discovery of a single compound capable of replacing monacolin K,” he said. “At the moment, there is simply no standalone ingredient that combines the same level of potency, clinical familiarity and market maturity.”
Some researchers are already exploring potential nutraceutical alternatives to red yeast rice, with studies showing that botanical blends can improve blood sugar control, lower triglycerides and LDL cholesterol, higher HDL and better insulin sensitivity compared with placebo.
Others argue that the industry has adopted a reductionist approach to cardiovascular health.
Ingredient distributor ACI Group, for one, contends that EU restrictions on monacolins have exposed a “fundamental flaw” in how heart health has been approached and that the industry has relied too heavily on single-ingredient, LDL cholesterol-lowering approaches, reducing cardiovascular health to one metric.
Looking ahead, Sam Lubbock Smith, business development manager at ACI Group, said that the future of heart health must lie not in finding alternatives to monacolins, but in redesigning products around integrated, systems-based models aligned with how the body functions.
“We are not dealing with a substitution problem,” he said. “We are dealing with a systems problem that the category has never properly addressed.”
